CSR Electrolyte Management in Renal Disease 2 — Questions and Answers

Question 1: A hemodialysis patient consistently has pre-dialysis serum bicarbonate of 17 mEq/L. What dietary intervention, in addition to oral sodium bicarbonate supplementation, can help correct metabolic acidosis?

Increasing dietary protein to generate more bicarbonate
Increasing intake of base-producing foods: fruits and vegetables (with attention to potassium content) (Correct answer)
Eliminating all dairy products to reduce acid load
Increasing dietary sodium to enhance bicarbonate retention

Correct answer: Increasing intake of base-producing foods: fruits and vegetables (with attention to potassium content)

Fruits and vegetables produce bicarbonate precursors (organic anions like citrate, malate) when metabolized. A diet rich in plant foods increases dietary alkali load, helping correct metabolic acidosis in CKD. Potassium content must be monitored in HD patients.

The net endogenous acid production (NEAP) from diet is determined by the balance of acid-generating foods (animal proteins generate sulfuric acid from methionine/cysteine catabolism) and base-generating foods (fruits/vegetables provide organic anions that are metabolized to bicarbonate). Potential renal acid load (PRAL) equations quantify dietary acid load. Shifting diet toward more fruits/vegetables reduces NEAP and increases dietary alkali, complementing sodium bicarbonate therapy. In HD patients, this must be balanced against potassium content — lower-potassium fruits/vegetables (apples, berries, cabbage, cauliflower, green beans) can provide alkali benefit without worsening hyperkalemia. Goraya et al. (2014) showed fruits/vegetables reduced CKD progression as effectively as bicarbonate supplementation.

Question 2: Which statement BEST describes the management of hypermagnesemia in an end-stage renal disease patient on hemodialysis?

Dietary magnesium is unrestricted because dialysis removes all excess magnesium
Avoid magnesium-containing medications (antacids, laxatives) and foods excessively high in magnesium; dialysate magnesium concentration can be adjusted for severe cases (Correct answer)
Hypermagnesemia requires emergency kidney transplant
Administer IV calcium gluconate as definitive treatment for all hypermagnesemia cases

Correct answer: Avoid magnesium-containing medications (antacids, laxatives) and foods excessively high in magnesium; dialysate magnesium concentration can be adjusted for severe cases

In ESRD, the kidney cannot excrete excess magnesium, so magnesium-containing medications (Maalox, Milk of Magnesia, magnesium-containing laxatives) are the most common cause of dangerous hypermagnesemia. Dietary and medication restriction plus dialysate concentration adjustment are the management strategies.

Hypermagnesemia in ESRD: normal serum Mg 1.7–2.2 mg/dL; HD patients typically run 2.0–3.0 mg/dL (mild elevation). Severe hypermagnesemia (> 6 mg/dL) causes: nausea, bradycardia, hypotension, loss of deep tendon reflexes, respiratory depression, cardiac arrest. Primary causes: magnesium-containing antacids (Maalox, Mylanta, magnesium hydroxide), cathartics (Epsom salts, Milk of Magnesia, magnesium citrate laxatives), magnesium-containing enemas. Management: (1) discontinue all Mg-containing products; (2) for life-threatening cases: IV calcium gluconate (cardiac antagonism), increase HD frequency or use low-Mg dialysate (dialysate Mg can be reduced to 0.25 mEq/L); (3) dietary counseling: avoid excess nuts, seeds, chocolate in the setting of clinical hypermagnesemia. Educating patients to avoid OTC magnesium-containing products is a critical dietitian responsibility.

Question 3: In dialysis patients, 'rebound hyperkalemia' can occur within hours after dialysis. Which physiological mechanism PRIMARILY explains this phenomenon?

Rapid re-absorption of potassium from the gut after dialysis
Shift of potassium from the intracellular compartment back to the extracellular space following removal of dialysis-induced alkalosis effects (Correct answer)
Increased dietary potassium absorption due to post-dialysis hunger
Residual kidney function secreting potassium back into the blood

Correct answer: Shift of potassium from the intracellular compartment back to the extracellular space following removal of dialysis-induced alkalosis effects

During dialysis, potassium is removed rapidly from plasma, but intracellular potassium equilibrates slowly. Post-dialysis, the electrochemical gradient drives K+ back from the intracellular compartment to plasma (rebound). Correction of dialysis-induced alkalosis also shifts K+ back extracellularly.

During HD, approximately 60–80 mEq of potassium is removed per session (3–4 hours). The extracellular fluid (ECF) compartment equilibrates quickly with dialysate, but the intracellular compartment (which holds 98% of body potassium, ~3500 mEq) equilibrates more slowly via Na+/K+-ATPase. Post-dialysis, the K+ gradient from intracellular to extracellular drives K+ movement back out of cells, causing serum K+ to rebound by 0.5–2.0 mEq/L within 30–120 minutes. Additionally, dialysis-induced metabolic alkalosis (bicarbonate-rich dialysate) initially drives K+ into cells during dialysis; as pH normalizes post-dialysis, K+ shifts back extracellularly. High-potassium meal immediately post-dialysis further worsens the rebound. Patients should avoid high-K+ foods in the first 2–4 hours after dialysis.

Question 4: Which phosphate binder is MOST appropriate for a CKD Stage 5D patient with both hyperphosphatemia AND iron-deficiency anemia?

Calcium carbonate
Sevelamer carbonate
Sucroferric oxyhydroxide (Velphoro) or ferric citrate (Auryxia) (Correct answer)
Lanthanum carbonate

Correct answer: Sucroferric oxyhydroxide (Velphoro) or ferric citrate (Auryxia)

Ferric citrate (Auryxia) and sucroferric oxyhydroxide (Velphoro) are iron-based phosphate binders that simultaneously bind dietary phosphate and provide systemic iron (via absorption of released iron), addressing both hyperphosphatemia and iron-deficiency anemia.

Iron-based phosphate binders offer dual benefits in iron-deficient HD patients: Ferric citrate (Auryxia): binds phosphate in the GI lumen; released citrate facilitates iron absorption, providing 200–400 mg of absorbed elemental iron per month. Clinical trials show ferric citrate reduces IV iron requirements and erythropoietin dose by 30–40% in HD patients while controlling phosphorus. Sucroferric oxyhydroxide (Velphoro): binds phosphate via an iron-based mechanism (less systemic iron absorption than ferric citrate). Preferred over calcium-containing binders in patients at risk for hypercalcemia or vascular calcification, and over sevelamer when iron supplementation is also needed. Monitoring: ferritin, transferrin saturation, hemoglobin response, and serum phosphorus levels guide therapy optimization.

Question 5: A dialysis patient develops sudden onset swelling of the tongue and difficulty swallowing. Serum calcium is 6.8 mg/dL (corrected). Which nutritional intervention is MOST urgently indicated?

Immediately restrict dietary calcium to prevent further toxicity
Ensure adequate calcium and vitamin D supplementation, and alert the medical team for IV calcium gluconate if severe hypocalcemia is causing tetany/laryngospasm (Correct answer)
Increase phosphorus intake to balance the low calcium
Administer high-dose oral sodium bicarbonate

Correct answer: Ensure adequate calcium and vitamin D supplementation, and alert the medical team for IV calcium gluconate if severe hypocalcemia is causing tetany/laryngospasm

Corrected serum calcium of 6.8 mg/dL represents severe hypocalcemia. Hypocalcemia can cause laryngospasm and tetany (emergency). The immediate response is to alert the medical team and provide calcium support; IV calcium gluconate is the emergency treatment.

Severe hypocalcemia (ionized Ca < 1.0 mmol/L or corrected total Ca < 7.5 mg/dL) can cause: neuromuscular excitability, Chvostek's sign (facial nerve tapping causes facial muscle twitch), Trousseau's sign (BP cuff inflation causes carpopedal spasm), tetany, laryngospasm (tongue swelling, dysphagia, stridor), and seizures. In dialysis patients, causes include: post-parathyroidectomy (hungry bone syndrome), cinacalcet therapy (lowers Ca), IV bisphosphonates, or low-calcium dialysate. Emergency: IV calcium gluconate 1–2 g IV over 10–20 minutes. Nutritional follow-up: ensure adequate calcium intake (1000–1200 mg/day from diet and supplements), adequate active vitamin D (calcitriol or analogs for CKD patients), and careful titration of calcimimetics. Monitor corrected calcium (or ionized calcium) regularly.

Question 6: In the context of CKD mineral and bone disorder (CKD-MBD), fibroblast growth factor 23 (FGF-23) plays a key role in mineral metabolism. Which of the following correctly describes FGF-23's action?

FGF-23 stimulates 1α-hydroxylase in the kidney, increasing calcitriol production
FGF-23 inhibits 1α-hydroxylase (reducing calcitriol) and promotes phosphaturia; elevated in CKD as a compensatory response to phosphate retention (Correct answer)
FGF-23 directly stimulates PTH release from the parathyroid gland
FGF-23 activates osteoclasts, causing bone resorption and hypercalcemia

Correct answer: FGF-23 inhibits 1α-hydroxylase (reducing calcitriol) and promotes phosphaturia; elevated in CKD as a compensatory response to phosphate retention

FGF-23 is secreted by osteocytes in response to phosphate loading. It inhibits renal 1α-hydroxylase (reducing calcitriol), reduces sodium-phosphate cotransporter expression in the proximal tubule (promoting phosphaturia), and is markedly elevated in CKD as kidneys fail to respond.

FGF-23 is secreted by bone osteocytes/osteoblasts in response to dietary phosphate loading. Its co-receptor Klotho (expressed in the distal tubule, parathyroid, and choroid plexus) is required for signaling. FGF-23 actions: (1) Inhibits 1α-hydroxylase → ↓ calcitriol → ↓ intestinal Ca/P absorption; (2) Downregulates NaPi-IIa and NaPi-IIc phosphate cotransporters in the proximal tubule → phosphaturia; (3) Inhibits PTH secretion (direct effect in CKD is overwhelmed by hypocalcemia stimulus). In early CKD (Stage 2–3), FGF-23 rises as the compensatory mechanism to maintain phosphorus within normal range. As Klotho expression falls with CKD progression, FGF-23 resistance develops, and serum phosphorus rises. Markedly elevated FGF-23 (>1000 RU/mL) is an independent predictor of mortality in CKD. Dietary phosphate restriction is the primary nutritional strategy to reduce FGF-23.

CSR Electrolyte Management in Renal Disease 2

A hemodialysis patient consistently has pre-dialysis serum bicarbonate of 17 mEq/L.
What dietary intervention, in addition to oral sodium bicarbonate supplementation, can help correct metabolic acidosis?